Chemistry: analytical and immunological testing – Biospecific ligand binding assay
Reexamination Certificate
2003-05-14
2009-02-17
Kim, Young J (Department: 1637)
Chemistry: analytical and immunological testing
Biospecific ligand binding assay
C530S350000
Reexamination Certificate
active
07491550
ABSTRACT:
The invention provides a human NMU2 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of NMU2 as well as pharmaceutical compositions comprising such compounds.
REFERENCES:
patent: 7108969 (2006-09-01), Warrington et al.
patent: 7163799 (2007-01-01), Liu et al.
patent: 2 399 052 (2001-08-01), None
patent: 0125269 (2001-04-01), None
patent: 0136473 (2001-05-01), None
Holt et al. The use of recombinant antibodies in proteomics. Current Opinion in Biotechnology, 11(5):445-9, Oct. 2000.
Banks et al. Proteomics: new perspectives, new biomedical opportunities. The Lancet, 356(9243):1749-56, Nov. 2000.
Crawford et al. The biological importance of measuring individual variation. The Journal of Experimental Biology, 210(9):1613-21, 2007.
Boorman et al. Variation in the hepatic gene expression in individual male Fischer rats. Toxicologic Pathology, 33:102-110, 2005.
Rao et al. Inflammatory biomarkers and cardiovascular risk: association or cause and effect? Seminars in Dialysis 19(2):129-135, 2006.
Butcher, S.P. Target discovery and validation in the post-genomic era. Neurochemical Research, 28(2):367-71, Feb. 2003.
Torres et al. Mice genetically deficient in neuromedin U receptor 2, but not neuromedin U receptor 1, have impaired nociceptive responses. Pain 130:267-278, 2007.
Dass et al. Neuromedin U can exert colon-specific, enteric nerve-mediated prokinetic activity, via a pathway involving NMU1 receptor activation. British Journal of Pharmacology 150:502-8, 2007.
May et al. Laboratory Technology Trends: Drug Discovery: 1 Improving Direction in Drug Discovery [online], Feb. 15, 2002 [retrieved on Sep. 23, 2007], retrieved from <URL:www.sciencemag.org/products/drugdiscovery.dtl>.
Chu et al. Cardiovascular actions of central neuromedin U in conscious rats. Regulatory Peptides 105:29-34 (2002).
GenBank AF292402 [online] Dec. 11, 2000 [retrieved on Oct. 20, 2008] retrieved from: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=9944989.
Howard, A. D., et al., “Identification of Receptors for Neuromedin U and its Role in Feeding”, Nature, 406(6791): 70-74 (Jul. 2000).
Raddatz, R., et al., “Identification and Characterization of Two Neuromedin U Receptor Differentially Expressed in Peripheral Tissues and the Central Nervous System”, J. Biol. Chem., 275(42): 32452-32459 (Oct. 2000).
Bers, “Calcium Fluxes Involved in Control of Cardiac Myocyte Contraction.” Circ Res. 2000:87, 275-281.
Brüggemeier Ulf
Geerts Andreas
Golz Stefan
Banner & Witcoff , Ltd.
Bayer Healthcare AG
Kim Young J
Woolwine Samuel
LandOfFree
Diagnostics and therapeutics for diseases associated with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostics and therapeutics for diseases associated with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostics and therapeutics for diseases associated with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4138545